Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention



Status:Completed
Conditions:Lupus, Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:5/19/2016
Start Date:September 2003
End Date:July 2006

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?

The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in
patients with systemic lupus by measuring:

1. changes in brachial artery flow-mediated dilatation (FMD) and

2. changes in biomarkers of cardiovascular risk. Patients will be enrolled in a
randomized, double-blinded crossover trial of DHEA or placebo for ten weeks, then
crossed over to the alternate treatment arm after a six-week washout period.

HYPOTHESIS: Dehydroepiandrosterone (DHEA) administration in premenopausal women with SLE
modifies cardiovascular risk by improving vascular endothelial function and other biomarkers
associated with cardiovascular heart disease.


Inclusion Criteria:

- Female

- Member of the Michigan Lupus Cohort

- Meet the American College of Rheumatology (ACR) criteria for SLE

- Premenopausal

Exclusion Criteria:

- Smoker

- Diabetic

- Prednisone dose > 10 mg
We found this trial at
1
site
University of Michigan
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials